Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering

Each offering unit includes two immediately exercisable Series D Warrants with an initial $0.66 exercise price.

Rhea-AI Summary

Sunshine Biopharma (SBFM) priced a public offering expected to raise approximately $6.0 million in gross proceeds on a reasonable best efforts basis.

The offering comprises 10,909,083 Common Units or Pre-Funded Units, priced at $0.55 or $0.54999 each, respectively. Each unit contains one common share or one Pre-Funded Warrant, plus two Series D Warrants, each to purchase one common share at an initial exercise price of $0.66. Series D Warrants are immediately exercisable and expire five years after initial issuance. Closing is expected on or about October 9, 2026, subject to customary closing conditions. Gross proceeds are before placement agent fees and other offering expenses. The company expects to use net proceeds for general corporate purposes and working capital.

1 point · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 4 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point. Forward-looking: it has not happened yet and may not happen.Public offering is expected to raise approximately $6.0 million in gross proceeds. 2.2× market cap

Negative

• Major point. Forward-looking: it has not happened yet and may not happen.10,909,083 Common Units or Pre-Funded Units at $0.55 or $0.54999, respectively, introduce shareholder dilution.
• Minor point. Forward-looking: it has not happened yet and may not happen.Two Series D Warrants per unit, initially exercisable at $0.66 per share, create potential additional dilution.
• Minor point. Forward-looking: it has not happened yet and may not happen.Placement agent fees and other offering expenses will reduce proceeds available to the company.
• Minor pointOffering uses a reasonable best efforts basis rather than a firm underwriting commitment.

News Explained

The offering is priced but not yet closed; if completed, its common shares and warrant exercises would increase the share count and reduce existing holders’ ownership percentages.

Argus 15 min delay 130 alerts

-34.54% vs previous close $0.46 last price 53489.5x rel. volume Open Argus

Details

Market move: SBFM -34.54% vs previous close. $6.0 million public offering

$0.42 – $1.32 Day Range

$1.78M Market Cap

On Oct 8, the day this news came out, the latest delayed price for SBFM is 34.54% below the previous close. Our momentum scanner has recorded 130 alerts for this stock so far that day. The latest delayed price is $0.46. Relative volume is exceptionally heavy at 53489.5x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Expected gross proceeds: approximately $6.0 million Units offered: 10,909,083 Common Units or Pre-Funded Units Common Unit price: $0.55 per Common Unit +5 more

Expected gross proceeds

approximately $6.0 million

Before placement agent fees and other offering expenses

Units offered

10,909,083 Common Units or Pre-Funded Units

Public offering

Common Unit price

$0.55 per Common Unit

Public offering price

Pre-Funded Unit price

$0.54999 per Pre-Funded Unit

Public offering price

Series D Warrants per unit

2

Each Common Unit or Pre-Funded Unit

Series D Warrant exercise price

$0.66 per share

Initial exercise price

Series D Warrant term

5 years

Expires after the initial issuance date

Expected closing

October 9, 2026

Subject to customary closing conditions

Key Terms

pre-funded warrant, best efforts, form s-1

3 terms

pre-funded warrant financial

"one (1) share of Common Stock or one (1) Pre-Funded Warrant"

A pre-funded warrant is a financial instrument that gives the holder the right to buy shares of a company's stock at a set price, with most of the purchase cost already paid upfront. It functions like a nearly fully paid option, allowing investors to secure shares quickly while minimizing the amount of additional money they need to invest later. This helps investors gain ownership rights efficiently, often used to avoid certain regulatory restrictions or to prepare for future stock purchases.

best efforts financial

"made on a reasonable best efforts basis"

A contractual promise to make a genuine, diligent effort to achieve a specified result without guaranteeing the outcome. For investors, it means a counterparty (for example, an underwriter or service provider) must work hard to deliver an outcome but is not legally required to produce a specific result, so the investor retains some risk; think of it like hiring someone to try their hardest to sell your house rather than promising they will sell it.

form s-1 regulatory

"A registration statement on Form S-1"

A Form S-1 is the registration filing a company submits to the U.S. Securities and Exchange Commission when it plans to offer stock to the public, most commonly for an initial public offering. Think of it as the company’s full disclosure packet or blueprint: it contains audited financials, business description, management background, risk factors and details of the offering, giving investors the information needed to judge the company’s financial health and potential risks before buying shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FORT LAUDERDALE, FL / ACCESS Newswire / October 8, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializing in generic and specialty prescription medications, including drugs in the areas of oncology and antivirals, today announced the pricing of a public offering made on a reasonable best efforts basis with gross proceeds to the Company expected to be approximately $6.0 million, before deducting placement agent fees and other offering expenses payable by the Company.

The offering consists of 10,909,083 Common Units (or Pre-Funded Units), each consisting of (i) one (1) share of Common Stock or one (1) Pre-Funded Warrant and (ii) two (2) Series D Warrants to purchase one (1) share of Common Stock per warrant at an initial exercise price of $0.66. The public offering price per Common Unit is $0.55 (or $0.54999 per Pre-Funded Unit, which is equal to the public offering price per Common Unit minus an exercise price of $0.00001 per share under the Pre-Funded Warrants). The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until exercised in full. The Series D Warrants will be exercisable immediately and expire five years after the initial issuance date. The exercise price and number of shares issuable under the Series D Warrants are subject to adjustment as described in more detail in the final prospectus to be filed in connection with the offering.

The transaction is expected to close on or about October 9, 2026, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering for general corporate purposes and working capital.

Aegis Capital Corp. is acting as the exclusive placement agent for the offering. Sichenzia Ross Ference Carmel LLP is acting as counsel to the Company. Kaufman & Canoles, P.C. is acting as counsel to Aegis Capital Corp.

A registration statement on Form S-1 (No. 333-299274) previously filed with the U.S. Securities and Exchange Commission (the "SEC") on October 2, 2026 was declared effective by the SEC on October 7, 2026. The offering is being made only by means of a prospectus. A final prospectus describing the terms of the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov. Electronic copies of the final prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010. Before investing in this offering, interested parties should read the prospectus in its entirety, which provides more information about the Company and such offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Sunshine Biopharma Inc.

Sunshine Biopharma currently has 61 generic prescription drugs on the market in Canada and
approximately 11 additional drugs expected to be launched in the remainder of 2026. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small-molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company's product development and business prospects, the closing of the offering, and the use of proceeds from the offering, and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans, including the risk factors described in the Company's documents filed with the Securities and Exchange Commission. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned as a result of these risks. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

For more information, please contact:

Camille Sebaaly, CFO
Direct Line: 514‑814‑0464
camille.sebaaly@sunshinebiopharma.com

SOURCE: Sunshine Biopharma Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much is Sunshine Biopharma's public offering expected to raise, and what is the unit price?

The offering is expected to raise approximately $6.0 million in gross proceeds, with Common Units priced at $0.55 and Pre-Funded Units at $0.54999. The offering comprises 10,909,083 units. Gross proceeds exclude placement agent fees and other offering expenses payable by the company.

When is Sunshine Biopharma's public offering expected to close?

The offering is expected to close on or about October 9, 2026, subject to satisfaction of customary closing conditions.

How do Sunshine Biopharma's Pre-Funded Warrants work?

Each Pre-Funded Warrant has an exercise price of $0.00001 per share, is immediately exercisable and remains exercisable until exercised in full. The $0.54999 Pre-Funded Unit price equals the $0.55 Common Unit price minus that exercise price.

Can Sunshine Biopharma's Series D Warrant terms be adjusted?

The exercise price and number of shares issuable under the Series D Warrants are subject to adjustment. The adjustment provisions will be described in more detail in the final prospectus to be filed in connection with the offering.